Skip to main content

Regeneron Pharmaceuticals EYLEA HD And EYLEA revenue

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026 · Market value $102.5B

EYLEA HD And EYLEA revenue at Regeneron Pharmaceuticals came to $1.1B for the quarter to 30 Sep 2026, down 1.1% from a year earlier.

As Regeneron Pharmaceuticals reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$1.5BDec 2023$1.4BMar 2024$1.5BJun 2024$1.5BSep 2024$1.5BDec 2024$1.0BMar 2025$1.1BJun 2025$1.1BSep 2025$1.1BDec 2025$941.5MMar 2026$1.0BJun 2026$1.1BSep 2026
Regeneron Pharmaceuticals EYLEA HD And EYLEA revenue, every reported period
Period endingEYLEA HD And EYLEA revenueChange on a yearFiled
30 Sep 2026$1.1Bdown 1.1%30 Oct 2026
30 Jun 2026$1.0Bdown 12.1%30 Jul 2026
31 Mar 2026$941.5Mdown 9.7%29 Apr 2026
31 Dec 2025$1.1Bdown 27.5%4 Feb 2026
30 Sep 2025$1.1Bdown 27.7%28 Oct 2025
30 Jun 2025$1.1Bdown 25.2%1 Aug 2025
31 Mar 2025$1.0Bdown 25.6%29 Apr 2025
31 Dec 2024$1.5Bup 2.4%5 Feb 2025
30 Sep 2024$1.5Bup 3.1%31 Oct 2024
30 Jun 2024$1.5Bup 2.3%1 Aug 2024
31 Mar 2024$1.4Bdown 2.2%2 May 2024
31 Dec 2023$1.5B—5 Feb 2024
30 Sep 2023$1.5B—2 Nov 2023
30 Jun 2023$1.5B—3 Aug 2023
31 Mar 2023$1.4B—4 May 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Regeneron Pharmaceuticals: Collaboration revenue · Net product sales · Libtayo revenue · Lynozyfic revenue · EYLEA HD revenue · EYLEA revenue · Praluent revenue · Evkeeza revenue · financial statements

Every KPI and segment of REGN, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.